Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Zhen Wang

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Cancer Communications (London, England)|January 20, 2021
Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcomeWu-Tong Ju, Ying Liu, Li-Zhen Wang, et al.
Nature Communications|September 14, 2022
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinomaWu-Tong Ju, Rong-Hui Xia, Dong-Wang Zhu, et al.
Oncotarget|July 1, 2015
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinomaLai-ping Zhong, Chen-ping Zhang, Guo-xin Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinomaLai-ping Zhong, Chen-ping Zhang, Guo-xin Ren, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Cancer Communications (London, England)|January 20, 2021
Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcomeWu-Tong Ju, Ying Liu, Li-Zhen Wang, et al.
Nature Communications|September 14, 2022
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinomaWu-Tong Ju, Rong-Hui Xia, Dong-Wang Zhu, et al.
Oncotarget|July 1, 2015
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinomaLai-ping Zhong, Chen-ping Zhang, Guo-xin Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinomaLai-ping Zhong, Chen-ping Zhang, Guo-xin Ren, et al.
Pageof 13